Lease Liability Payments - 2021
Neurocrine Biosciences Lease Liability Payments - 2021 increased by 14.3% to $4.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.3%, from $3.50M to $4.00M. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
Higher payments indicate significant near-term cash requirements for leased assets, while lower payments suggest reduced short-term liquidity pressure from lease commitments.
Detailed definition
This metric quantifies the specific portion of total lease liabilities, encompassing both operating and finance leases,...
Peer comparison
This is a standard liquidity disclosure across all public companies following ASC 842 or IFRS 16 accounting standards, allowing for direct comparison of short-term lease-related cash outflows.
lease_liability_payments_2021Historical Data
| Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $1.70M | $1.70M | $2.70M | $3.50M | $3.50M | $3.50M | $3.50M | $4.00M |
| QoQ Change | — | +0.0% | +58.8% | +29.6% | +0.0% | +0.0% | +0.0% | +14.3% |
| YoY Change | — | — | — | +105.9% | +105.9% | +29.6% | +0.0% | +14.3% |
Lease Liability Payments - 2021 at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's lease liability payments - 2021?
- Neurocrine Biosciences (NBIX) reported lease liability payments - 2021 of $4.00M in Q1 2026.
- How has Neurocrine Biosciences's lease liability payments - 2021 changed year-over-year?
- Neurocrine Biosciences's lease liability payments - 2021 increased by 14.3% year-over-year, from $3.50M to $4.00M.
- What does lease liability payments - 2021 mean?
- The total cash outflow required to settle lease obligations due within the 2021 fiscal year.